Clinical trial NCT04793152: Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
Official title: Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: MRSA
Keywords: vancomycin
MRSA
trough
AUC
Lead sponsor: Queen's University
Sponsor class: OTHER
Collaborators: name: Physician Services Incorporated
name: Canadian Institutes of Health Research (CIHR)
First posted: 2021-03-11
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intravenous vancomycin is considered first line therapy for serious methicillin-resistant Staphylococcus aureus (MRSA) infections including bacteremia, central nervous system infection, pneumonia, pleural space infection, bone or joint infection, prosthetic joint infection and deep abscesses. The effectiveness and toxicity of vancomycin depend on its dosing and chosen target. The most recent guidelines suggest targeting area under the curve over 24 hours over minimum inhibitory concentration (AUC/MIC) of 400 to 600. Implementation of AUC/MIC requires Bayesian software that can be variable, costly, complicated and time consuming. Ideally, AUC/MIC dosing would also require susceptibility testing by broth microdilution, which is not commonly done. It is recommended to target AUC of 400 to 600 assuming a MIC of 1ug/mL when MIC by broth microdilution is not known. Targeting a trough level of 10 to 15mg/L may be a reasonable and more practical alternative without compromising effectiveness. We will be conducting a randomized controlled non-inferiority trial to compare intravenous vancomycin dosing strategy targeting a trough level of 10 to 15mg/L versus AUC of 400 to 600 assuming a MIC of 1ug/mL by broth microdilution for serious MRSA infections. The primary outcome will be treatment failure, which is a composite of mortality and microbiologic failure at 90 days. We hypothesize that targeting a trough level of 10 to 15mg/L is non-inferior to targeting a AUC of 400 to 600 in terms of treatment failure. The criterion for non-inferiority is that a two-sided 95% confidence interval for difference in risk of treatment failure will lie within the non-inferiority margin of 10%.


Eligibility criteria: Inclusion Criteria:

* Adult patients with serious MRSA infections based on culture results including bacteremia, pneumonia, pleural space infection, central nervous system infection, bone infection, septic arthritis, prosthetic joint infection, and deep abscess
* Enrolment within 4 days from date of MRSA culture collection
* Patient either currently not on vancomycin or has received vancomycin for 4 days or less

Exclusion Criteria:

* Vancomycin minimum inhibitory concentration (MIC) ≥2ug/mL
* Patient is palliative or expected to die in the next 48 hours, or requires critical care resources but will not receive it due to advanced care directives
* History of type 1 hypersensitivity reaction to vancomycin
* Patients on intermittent hemodialysis or peritoneal dialysis

Primary outcomes:
measure: Treatment failure
timeFrame: 90 days
Secondary outcomes:
measure: Major adverse kidney events
timeFrame: 90 days
measure: Vancomycin associated nephrotoxicity
timeFrame: 90 days
measure: Renal replacement therapy
timeFrame: 90 days
measure: Time to target
timeFrame: 90 days
measure: Day 3 AUC
timeFrame: 3 days
measure: Vancomycin cost
timeFrame: 90 days
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Hamilton Health Sciences
state: Ontario
city: Hamilton
country: Canada
facility: St. Joseph's Healthcare Hamilton
state: Ontario
city: Kingston
country: Canada
facility: Kingston Health Sciences Centre
state: Ontario
city: Montreal
country: Canada
facility: McGill University Health Centre
state: Quebec
Study officials:
affiliation: Queen's University
name: Anthony D Bai, MD
role: PRINCIPAL_INVESTIGATOR
References: